

Axinn Obtains Favorable Decision in FDA Suit


NEWS | LESS THAN 1 MIN READ

January 15, 2013

Axinn secured a favorable outcome for client Alvogen Inc. in ViroPharma Inc.'s case against the U.S. Food and Drug Administration regarding generic forms of the antibiotic Vancocin (vancomycin). The Axinn team assisted Alvogen Inc. in intervening on the side of the government in order to allow Alvogen to continue to market its generic vancomycin product under its approved Abbreviated New Drug Application.

Judge Huvelle's Memorandum Opinion stated that "the FDA acted well within its discretion in denying three-year exclusivity to ViroPharma and in approving the ANDAs of intervenor-defendants."

Related People



Nicholas E.O. Gaglio

Related Services

Intellectual Property

To subscribe to our publications, [click here](#).

Featured Insights

- GCR Live: Law Leaders Europe 2025
SPEAKING ENGAGEMENT ANTITRUST
- AHLA Annual Meeting 2025
SPEAKING ENGAGEMENT ANTITRUST
- SABA North America Annual Conference 2025
SPEAKING ENGAGEMENT ANTITRUST
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses
WEBINAR ANTITRUST
- Volunteer Lawyers for the Arts – Champions of the Arts Awards and Gala 2025
SPONSORSHIP ANTITRUST
- NJSBA Annual Meeting and Convention 2025
SPEAKING ENGAGEMENT INTELLECTUAL PROPERTY
- Cost-Effective and Efficient IP Litigation Strategies – Making Paragraph IV Litigation Work for You
WEBINAR INTELLECTUAL PROPERTY
- Hartford HealthCare Black and Red Gala 2025
SPONSORSHIP ANTITRUST
- Informa CompLaw Antitrust West Coast Conference 2025
SPEAKING ENGAGEMENT ANTITRUST

- Recent Decision Shows the Heavy Burden of Actual Malice in Defamation Suits
- AXINN VIEWPOINTS LITIGATION & TRIALS**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved